Pharming jumps after upbeat revenue guidance for 2026

Pharming

03/02/2026 08:45

** Shares in Pharming Group PHAR.AS are up 7.6% after the Dutch biotech company shared a 2026 guidance above market expectations

** The company forecasts annual revenue growth of 8%-13% driven by Joenja and Ruconest, its treatments for rare diseases

** Jefferies analyst Lucy Codrington says the guidance surpasses both Jefferies' and "sparse consensus" estimates, reflecting "a strong outlook despite the recent Joenja paediatric setback"

** The stock is rebounding after it shed more than 16% on Monday, after the U.S. FDA issued a complete response letter for the Joenja paediatric application, which Jefferies called "disappointing"

** Codrington says that anticipated growth in Joenja's U.S. adult applications and future opportunities in non-U.S. markets appear to be key drivers for revenue expansion

** Pharming also expects 2026 operating expenses to be between $330-335 million

** Jefferies sees the increase in expected costs, attributed to intensified R&D activities, as a positive sign of Pharming's commitment to the development of its pipeline

(Reporting by Clement Martinot)

((Clement.Martinot@thomsonreuters.com;))